Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
Activity Details
|
|
|
|
336 * !
|
Tue, 7/31/2018,
10:30 AM -
12:20 PM
|
CC-West 224
|
|
Surrogate Endpoints: Bridging the Roles of Biology and Statistics for Clinical Outcome Prediction — Topic Contributed Papers
|
|
Biopharmaceutical Section
|
|
Organizer(s): Hong Tian, Janssen Pharmaceutical
|
|
Chair(s): Sue-Jane Wang, Center for Drug Evaluation and Research U.S. Food and Drug Administration
|
|
10:35 AM
|
On the Relationship Between the Causal-Inference and Meta-Analytic Paradigms for the Evaluation of Surrogate Endpoints
Geert Molenberghs, Universiteit Hasselt & Katholieke Universiteit Leuven
|
|
10:55 AM
|
Assessment of Biomarkers and Surrogate Endpoints in Drug Development
Ivan Chan, AbbVie Inc; Shu-Chih Su, Merck Research Labs
|
|
11:15 AM
|
Limitations of Progression Free Survival as a Surrogate Marker for Overall Survival in Oncology Trials
Robin Mogg, Merck Research Laboratories; Yiwei Zhang, Merck Research Laboratories
|
|
11:35 AM
|
Identifying and Validating Surrogate Endpoints for Overall Survial (OS) in Metastatic Castration-Resistant Prostate Cancer
Xiaowei Guan, Pfizer, Inc.; Michelle Casey, Pfizer, Inc.; De Phung, Astellas Pharma, Inc. ; Suha Sari, Pfizer, Inc.; Eren Demirhan, Pfizer, Inc.
|
|
11:55 AM
|
Discussant: Vladimir Dragalin, Janssen R&D
|
|
12:15 PM
|
Floor Discussion
|
|
